Newcells Biotech to develop a new skin metabolism model using iPSC derived skin cells

Newcells Biotech has been successful in partnering with Newcastle University to receive funding in a £100K phase I NC3R CRACK IT project to develop a new skin metabolism model using iPSC derived skin cells.

Working with academics Prof Mark Birch-Machin and Dr Peter Hanson from the Institute of Cellular Medicine, Newcells is using its expertise in cellular reprogramming and differentiation of iPSCs to provide cells that will be used to construct a new skin model that will enable understanding of skin metabolism of topical drugs and xenobiotics. The project titled Metaboderm was one of only three in the UK that received funding under the scheme and the project is sponsored by GSK, Unilever, Stiefel and Dstl.

You might also be interested in…
retinal pigmented epithelium (RPE)

Newcells Biotech Ltd. RPE Model to Improve Drug Retinal Toxicity Assessment

Retinal toxicity is an adverse side effect that can cause (usually irreversible) deterioration of a person’s vision, when taking certain medication. This has been seen for example in people taking Hydroxychloroquine for Malaria due to toxicity to the retinal cells.  The retinal pigmented epithelium (RPE) is